Novel approaches to reduce temozolomide resistance in glioblastoma multiforme: a review of the literature

WCRJ 2019; 6: e1431
DOI: 10.32113/wcrj_201911_1431

  Topic: Oncology     Category:

Abstract

Temozolomide (TMZ), an oral alkylating agent, is currently used as a part of standard treatment for glioblastoma multiforme (GBM). GBM is considered one of the most lethal forms of human cancers, and despite recent improvement in cancer therapy, it remains an incurable disease, with a rare long-term survival of the patients due to the rapid emergence of cell clones resistant to treatment. Like other chemotherapeutic agents, resistance to TMZ is the major therapeutic obstacle to effective therapy; thereby, the development of new therapeutic strategies is required to overcome this problem. In the present review, an overview of the recent works on the reduction of TMZ resistance is presented.

To cite this article

Novel approaches to reduce temozolomide resistance in glioblastoma multiforme: a review of the literature

WCRJ 2019; 6: e1431
DOI: 10.32113/wcrj_201911_1431

Publication History

Submission date: 18 Jun 2019

Revised on: 26 Aug 2019

Accepted on: 24 Oct 2019

Published online: 21 Nov 2019